Articles tagged with Drug Studies
Researchers demonstrate a new way to deliver medication to malignant brain tumors in mice, using a modified peptide that can penetrate the blood-brain barrier. The study shows promising results, with a 50% increase in survival rate for treated mice, and offers hope for future treatment breakthroughs.
A study published in PLOS ONE found that adults with type 2 diabetes taking metformin had a 45% lower risk of needing a breathing machine or dying from COVID-19 compared to those not taking the medication. The research team analyzed data from a large database and suggested metformin may be an effective treatment option for reducing COV...
The FDA approved Aduhelm for Alzheimer's treatment based on reduced amyloid levels in the brain, despite no significant clinical effect. The use of amyloid-PET scans is being questioned for its accuracy and reliability in measuring amyloid removal.
Studies found that sotrovimab reduced the risk of severe covid-19 outcomes by 46% compared to molnupiravir. However, no benefit was found for common heart drugs like ARBs in a randomised controlled trial.
The FDA's investigation into its own oversight of clinical trials reveals a concerning lack of surveillance, leaving room for scientific misconduct. Experts argue that the agency should inspect sites more frequently to ensure data quality and integrity.
A large registry-based study found lisdexamfetamine to be associated with the lowest risk of hospitalisation and death in people with amphetamine addiction. The medication showed a significant reduction in hospitalisation due to substance use disorder and any cause or death, while benzodiazepine and antidepressant use were linked to po...
A new prodrug called DRP-104 targets cancer cells' high demand for glutamine, eliminating them while sparing healthy tissues. The drug is in early-stage clinical trials for advanced solid tumors and shows promise as a safer alternative to existing treatments.
Researchers have identified potential new lead compounds for treating depression and anxiety disorders, which display reduced risk of drug abuse and adverse effects. These substances, derived from synthetic cathinone compounds, are known to release serotonin without significantly increasing dopamine levels in the brain.
A research team developed a vaccine targeting synthetic opioid fentanyl to block its entry into the brain, preventing fatal effects. The breakthrough could have major implications for treating Opioid Use Disorder, with potential relapse prevention capabilities.
A study by Okayama University researchers found that neuromedin U (NMU) is involved in metabolic processes but its 'anti-hunger' function may not be crucial for rats. Unlike mice, NMU expression is restricted in the rat brain and does not suppress feeding behavior.
The study aims to assess the effectiveness of recombinant Factor VIIa (rFVIIa) in decreasing bleeding in the brain of patients with intracerebral hemorrhage (ICH). ICH is a deadly stroke type with no effective treatment, and this trial seeks to improve outcomes.
Researchers at the University of Helsinki have identified a promising drug candidate, TYK2 inhibitor, for preventing type 1 diabetes. The study found that inhibiting TYK2 expression reduces the destruction of pancreatic beta cells, but may also reduce beta cell production in earlier stages.
The West Texas Pharmacology Core laboratory at TTUHSC will focus on two primary areas: drug development and pediatric cancer. The core aims to address obstacles in drug development, including limited pharmacology expertise for small biotech companies and low profitability for pediatric cancer drugs.
A UK Biobank study found that people with hypertension have a 22% higher chance of developing severe COVID-19. Successfully managing blood pressure through medication can significantly lower this risk. The study analyzed data from over 16,000 infected individuals.
Researchers have discovered two novel drugs that can block the growth and shrink the size of schwannoma tumors, a type of nerve sheath tumor found in the nervous system. The treatment works by inhibiting the Hippo signaling pathway, which is dysregulated in multiple types of cancer.
Researchers believe that changes in the brain's orexin system promote drug-seeking behavior and that existing insomnia treatments could reduce or eliminate cravings. Studies have shown that blocking this system reverses addiction in animals and reduces opioid cravings in human subjects.
Researchers discovered stem cells in mouse dorsal root ganglia (DRG) with the potential to regenerate lost sensory neurons and glia. These cells, known as satellite glia, can become activated and generate new glia and, to a lesser extent, neurons after injury.
Researchers conducted the largest clinical trial to date of psilocybin, finding a statistically significant rapid reduction in symptoms of depression. The study suggests that COMP360 psilocybin with psychological support could be an effective treatment strategy for people with treatment-resistant depression.
A new study found that a personalized 'precision' testing approach for people with stable chest pain led to more efficient evaluations and improved diagnosis of coronary artery disease. The approach involved assessing cardiovascular risk factors to identify low-risk individuals who may not benefit from further testing.
A new study found that rapid optimization of oral heart failure medications reduced the risk of dying or being readmitted for heart failure within six months after discharge. The STRONG-HF trial enrolled over 1,000 people hospitalized for acute heart failure and showed significant improvement in outcomes with high-intensity care.
Regular use of cholesterol-lowering and diabetes-control drugs may lessen the risk of age-related macular degeneration (AMD) in European populations. The pooled data analysis involved 38,694 participants and showed a 15% lower prevalence of any type of AMD with these medications.
A randomized controlled trial found that oral ENT-01 significantly improves constipation and possibly neurological symptoms in persons with Parkinson disease. The treatment is safe for up to 25 days, with a dose-dependent effect that persists beyond the treatment period.
Researchers found that two common diuretics, chlorthalidone and hydrochlorothiazide, had no difference in cardiovascular outcomes among study participants. However, those taking chlorthalidone showed a reduced risk of heart disease and death by an average of 27% among patients with a history of heart attack or stroke.
A new medication, pemafibrate, lowered triglyceride levels among adults with Type 2 diabetes, but did not decrease their cardiovascular risk. The study found that lowering triglyceride levels may not protect against cardiovascular disease in people with Type 2 diabetes.
A study published in the American Heart Association found that six common dietary supplements did not lower LDL cholesterol levels when compared to a low-dose statin medication or placebo. The research suggests that these supplements are unlikely to offer meaningful impact on cholesterol levels, and a heart-healthy lifestyle is still t...
A new study found that long-term treatment with intravenous iron improved symptoms and reduced recurrent hospitalizations among people with heart failure and iron deficiency. The treatment was associated with a significant benefit on reducing the risk of heart failure hospitalization and cardiovascular death.
A new study has shown that SGLT-2 inhibitors, a type of diabetes medication, can decrease cardiovascular risk in adults with chronic kidney disease. The meta-analysis included results from 13 major clinical trials and found a 28% lower risk of worsening kidney disease and death from cardiovascular disease.
A clinical trial found that early use of ECMO devices did not improve outcomes for adults with rapidly deteriorating or severe cardiogenic shock. Participants who received immediate ECMO therapy showed similar clinical outcomes as those receiving early conservative therapy, including treatment with inotropes and vasopressors.
A randomized study compared the effects of torsemide and furosemide in people with heart failure. The study found that both loop diuretics were effective in reducing death and hospitalization rates, with no significant clinical difference between the two medications.
A new study has shown that bivalirudin is a safer and more effective anticoagulant than heparin for treating heart attack patients. The trial found that bivalirudin significantly reduced death, major bleeding, and thrombosis in patients undergoing percutaneous coronary intervention.
A major randomized trial of pemafibrate found no reduction in rates of heart attack, stroke, or cardiovascular death over a five-year period, despite lowering triglycerides by 26 percent. Pemafibrate was effective at reducing remnant cholesterol levels but failed to demonstrate clinical benefits.
A new study published in Alzheimer's & Dementia found that telmisartan, a blood pressure medication, is associated with lower risk of Alzheimer's specifically in Black patients over 60. The study analyzed data from over 5 million patients and suggests that future clinical trials should prioritize minority populations to find or reinfor...
Researchers have found therapies that can help patients with relapsed multiple myeloma who tried CAR-T therapy, including bispecific antibodies and other types of CAR-T cell therapy. The study analyzed 79 patients and found that stem cell transplants and other drug combinations showed some efficacy in these patients.
Researchers at the University of Missouri have successfully used click chemistry to deliver radiopharmaceuticals specifically to tumors in large dogs with bone cancer, increasing effectiveness and minimizing circulation. This breakthrough could pave the way for click chemistry-based treatments for humans with cancer in the future.
A recent study found worsening disparities in cancer drug trial participant diversity from 2000 to 2018, highlighting systemic biases and unequal access to new treatments. The findings underscore the need for increased diversity in phase 1 clinical trials to ensure equitable access to life-saving treatments.
A multicentre clinical trial found that a single dose of COMP360 psilocybin significantly reduced depression symptoms in participants with treatment-resistant depression. The study, involving 233 participants, showed improved outcomes for those receiving the 25mg dose compared to the control group.
A new study published in the New England Journal of Medicine found that semaglutide, an approved obesity drug for adults, also helps adolescents with obesity lose weight and have healthier hearts. After 68 weeks, 72.5% of participants who received semaglutide had achieved at least 5% weight loss compared to just 17% on placebo.
A small clinical trial showed 40% of patients experienced progression-free survival when treated with a CD105 inhibitor, which prevented cancer cells from making splice variant proteins. This approach may resensitize select patients to androgen suppression therapy.
Researchers at the University of Cincinnati are awarded a $3.5 million NIH grant to examine how alcohol use alone or in combination with fentanyl affects HIV medications, including PrEP medication. The study aims to determine metabolite signatures and pharmacological biomarkers of PrEP in HIV-negative populations.
A new study found that only 12% of middle-aged adults are willing to participate in dementia prevention drug trials, citing concerns over the risks involved. The study suggests prioritizing those with a family history or perceived personal risk for dementia and communicating about trial safety could increase participation.
The Alpha Stem Cell Clinic will develop preclinical studies into early and later phase clinical trials with the goal of establishing advanced regenerative medicine treatments. The clinic will also foster greater collaboration with eight similar clinics across the state and educate the public about stem cell and related therapies.
Dr. Volpp's research on behavioral economics and health incentives has significantly advanced understanding of cardiovascular outcomes, leading to changes in benefit design and program offerings. He is also the founder of Penn Center for Health Incentives and Behavioral Economics.
A comparison of two cancer drugs reveals that life cycle management strategy is crucial for a drug's commercial success. The research found that product sales are closely linked to the number of approved indications and inter-organizational alliances.
A new daily anti-clotting pill, edoxaban, shows promise in preventing bleeding and clotting instances rare in children with heart conditions. The study's findings indicate edoxaban is a viable alternative to current treatments, eliminating injections and reducing frequent blood tests.
Researchers at Weill Cornell Medicine have developed a new computational method to map the architecture of human tissues in unprecedented detail. This approach enables powerful new diagnostic strategies for a wide range of diseases, including cancer and chronic conditions.
A large-scale comparison of direct oral anticoagulants has identified apixaban as the drug with the lowest risk of bleeding. The study, published in Annals of Internal Medicine, found that apixaban had a 19-28% lower risk of gastrointestinal bleeding compared to other DOACs.
In the ARROS-1 trial, 48% of patients achieved partial responses to NVL-520, with responses seen across all dose levels and in heavily pre-treated patients. The treatment also showed promise for brain metastases, with three out of three patients experiencing measurable response or no emergence of new metastases.
The TRIDENT-1 trial suggests that repotrectinib could be effective for treating ROS1 positive non-small cell lung cancer (NSCLC) in patients who have received other targeted treatments and those who have not. The drug showed promising results, with an objective response rate of 79% in patients not previously treated with a ROS TKI.
Researchers have successfully isolated parathyroid stem cells and maintained them in lab as organoids for an extended period. These patient-derived parathyroid organoids (PTOs) closely mimic human parathyroid tissue, enabling the study of parathyroid diseases and drug development.
A new experimental drug has shown promising results in treating liver cancer, with two patients experiencing a partial response to the treatment. The drug, NMS-01940153E, targets an enzyme that plays a critical role in cell division and growth, and its side effects are manageable.
A study found that nearly half of Medicaid beneficiaries who completed opioid rehab did not receive follow-up care or medication-assisted treatment within a month. Patients with prior prescriptions for opioid use disorder medications were 24% more likely to get follow-up care and medication.
A Phase Ib clinical trial found that sequential administration of PARP inhibitor olaparib and WEE1 inhibitor adavosertib is safe and well-tolerated, with promising signs of anti-tumor activity in patients with advanced cancers driven by DNA damage response mutations. The combination showed durable responses in patients with resistant c...
In a patient trial, the AKT inhibitor ipatasertib showed signs of effectiveness in treating advanced cancers. 22% of patients experienced tumor shrinkage, while 56% had stable disease. Further research is needed to understand why some patients responded and others did not.
A phase I clinical trial found that Omomyc (OMO-103) has few side effects and can stabilize disease in some patients. The treatment showed stabilization of disease in 8 out of 17 evaluable patients, including one patient with pancreatic cancer who remained on the study for over six months.
Dr. Christine E. Seidman, a renowned physician-scientist, has made groundbreaking discoveries in genetics and cardiomyopathy, leading to new pharmacological treatments. Her work has improved our understanding of disease risks and has led to unique targeted therapies.
The NCI-MATCH precision medicine cancer trial found a promising signal for the AKT inhibitor ipatasertib, meeting its primary endpoint with a 22% response rate in patients with rare AKT1 E17K tumor gene mutations. The study demonstrated clinically significant activity in patients, warranting additional studies.
RedHill Biopharma's Talicia demonstrates high potential for H. pylori eradication while minimizing systemic antibiotic exposure, outperforming generic rifabutin regimens. Movantik data shows improved patient quality of life and symptom improvement in opioid-induced constipation.
A new drug combination of cefepime and enmetazobactam has been found to be more effective in treating complicated urinary tract infections and acute pyelonephritis than a standard treatment. The study showed that the new combination was successful in treating 79% of patients, compared to 58.9% for the conventional treatment.
Studies on 18beta-glycyrrhetinic acid, human islet amyloid polypeptide (hIAPP), and fluoroquinolone derivatives explore new approaches to treating challenging diseases. Researchers aim to develop better therapeutics for liver diseases, which cause almost 2 million deaths worldwide every year.
Researchers have found a drug that targets the key, cancer-causing gene MYC has been able to inhibit its function safely and effectively. Eight out of 12 patients showed stabilisation of disease after treatment with OMO-103, with one patient experiencing a reduction in tumour-derived DNA circulating in the blood stream.